Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced […]
Ambagon Therapeutics’ $85 Million Series A Financing
Yangzhou Yuanbo’s $46 Million Bond Offering
Grandall advised Yangzhou Yuanbo on the offering. Yangzhou Yuanbo Investment and Development Co. executed its offering of USD 46 million senior unsecured fixed rate bond with […]
Yangzhou Yuanbo’s $46 Million Bond Offering
Grandall advised Yangzhou Yuanbo on the offering. Yangzhou Yuanbo Investment and Development Co. executed its offering of USD 46 million senior unsecured fixed rate bond with […]
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical […]
Aristea’s $63 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management & […]
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on […]